Skip to main content
Fig. 5 | BMC Complementary Medicine and Therapies

Fig. 5

From: Biochanin A abrogates osteoclastogenesis in type 2 diabetic osteoporosis via regulating ROS/MAPK signaling pathway based on integrating molecular docking and experimental validation

Fig. 5

BCA blocks osteoclast-specific gene expression. A Acp5, (B) Ctsk, (C) Mmp9, (D) Atp6v0d2 and (E) Nfatc1 gene expression levels were standardized to 18s expression. (F) Representative western blotting images of the effects of BCA on NFATc1, c-Fos, V-ATPase-d2, and CTSK. G-J Quantitative analysis of the fold change after BCA (10µM) treatment. Data were presented as the means ± SD; *P < 0.05, **P < 0.01 and ***P < 0.001 relative to RANKL-induced controls

Back to article page

BMC Complementary Medicine and Therapies

ISSN: 2662-7671

Contact us